HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tse, G. M. K. Articles by Yeung, D. K. W. Search for Related Content PubMed PubMed Citation Articles by Tse, G. M. K. Articles by Yeung, D. K. W. Social Bookmarking                      What's this? Hotlight (NEW!) What's Hotlight?

Characterization of Lesions of the Breast with Proton MR Spectroscopy: Comparison of Carcinomas, Benign Lesions, and Phyllodes Tumors

¹ Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, Chinese University of Hong Kong, Ngan Shing St., Shatin, Hong Kong, SAR China.
² Department of Radiology and Organ Imaging, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, Hong Kong SAR, China.
³ Present address: Department of Radiology, Kulliyyah of Medicine, International Islamic University Malaysia, PO Box 141, 25710 Kuantan, Pahang DM, Malaysia.
⁴ Department of Surgery, Prince of Wales Hospital, Shatin, Hong Kong SAR, China.
⁵ Department of Clinical Oncology, Prince of Wales Hospital, Shatin, Hong Kong SAR, China.

OBJECTIVE. Proton MR spectroscopy is a recently described technique with high sensitivity and specificity for differentiating breast carcinoma from benign lesions. We evaluated the possible relationship between spectroscopy results and the tumor proliferative index, angiogenesis, and HER2/neu oncogene overexpression.

SUBJECTS AND METHODS. We prospectively evaluated 19 breast carcinomas, 21 benign breast lesions (including 18 fibroadenomas, one fibrocystic change, one hamartoma, and one papilloma), and six phyllodes tumors (four benign, two of borderline malignancy) using proton MR spectroscopy. All lesions were larger than 1.5 cm. Tumor Ki-67 proliferative index, tumor angiogenesis, and HER2/neu oncogene overexpression were evaluated by immunohistochemistry of the histologic material.

RESULTS. Spectroscopy findings were positive in 17 (89%) of 19 carcinomas but negative for all benign lesions and phyllodes tumors (sensitivity, 89%; specificity, 100%). Significantly higher levels were obtained for all biologic parameters in carcinomas compared with benign lesions and phyllodes tumors. HER2/neu oncogene overexpression was present in 37% of carcinomas but not in other lesions. The two false-negative findings of breast carcinoma showed similar Ki-67 proliferative index and microvessel density compared with the remaining carcinomas, but both cases were negative for HER2/neu overexpression.

CONCLUSION. Proton MR spectroscopy is useful in the in vivo characterization of breast masses when the lesion exceeds 1.5 cm in maximal dimension. Spectroscopy is unable to reveal benign breast lesions and phyllodes tumors of benign and borderline malignancy. We suggest that a false-negative spectroscopic result may be related to an absence of HER2/neu overexpression in carcinoma of the breast.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Tozaki and E. Fukuma 1H MR Spectroscopy and Diffusion-Weighted Imaging of the Breast: Are They Useful Tools for Characterizing Breast Lesions Before Biopsy? Am. J. Roentgenol., September 1, 2009; 193(3): 840 - 849. [Abstract] [Full Text] [PDF]

				F. Sardanelli, A. Fausto, G. Di Leo, R. de Nijs, M. Vorbuchner, and F. Podo In Vivo Proton MR Spectroscopy of the Breast Using the Total Choline Peak Integral as a Marker of Malignancy Am. J. Roentgenol., June 1, 2009; 192(6): 1608 - 1617. [Abstract] [Full Text] [PDF]

				L. Bartella, S. B. Thakur, E. A. Morris, D. D. Dershaw, W. Huang, E. Chough, M. C. Cruz, and L. Liberman Enhancing Nonmass Lesions in the Breast: Evaluation with Proton (1H) MR Spectroscopy Radiology, October 1, 2007; 245(1): 80 - 87. [Abstract] [Full Text] [PDF]

				L. Bartella and W. Huang Proton (1H) MR Spectroscopy of the Breast RadioGraphics, October 1, 2007; 27(suppl_1): S241 - S252. [Abstract] [Full Text] [PDF]

				P. Stanwell and C. Mountford In Vivo Proton MR Spectroscopy of the Breast RadioGraphics, October 1, 2007; 27(suppl_1): S253 - S266. [Abstract] [Full Text] [PDF]

				L. Bartella, E. A. Morris, D. D. Dershaw, L. Liberman, S. B. Thakur, C. Moskowitz, J. Guido, and W. Huang Proton MR Spectroscopy with Choline Peak as Malignancy Marker Improves Positive Predictive Value for Breast Cancer Diagnosis: Preliminary Study Radiology, June 1, 2006; 239(3): 686 - 692. [Abstract] [Full Text] [PDF]

				R K Jacklin, P F Ridgway, P Ziprin, V Healy, D Hadjiminas, and A Darzi Optimising preoperative diagnosis in phyllodes tumour of the breast J. Clin. Pathol., May 1, 2006; 59(5): 454 - 459. [Abstract] [Full Text] [PDF]

				S. Meisamy, P. J. Bolan, E. H. Baker, M. G. Pollema, C. T. Le, F. Kelcz, M. C. Lechner, B. A. Luikens, R. A. Carlson, K. R. Brandt, et al. Adding in Vivo Quantitative 1H MR Spectroscopy to Improve Diagnostic Accuracy of Breast MR Imaging: Preliminary Results of Observer Performance Study at 4.0 T Radiology, August 1, 2005; 236(2): 465 - 475. [Abstract] [Full Text] [PDF]

				E. D. Yeh Characterization of Breast Lesions with Proton MR Spectroscopy Am. J. Roentgenol., November 1, 2003; 181(5): 1273 - 1274. [Full Text] [PDF]